Develops and sells branded pharmaceutical formulations for the Indian domestic market, with products across antibiotics (Stergiclav 625 and Smartyclav 625), CNS and psychiatric medications (Sterprax and Stergipam MD), pain management (Stergicet with paracetamol and tramadol), sleep aids (Sterpidem MD with zolpidem), and home healthcare devices including a digital blood pressure monitor. Royal Sense Limited sells all pharmaceutical products as prescription-only medicines under Schedule H classification. Through its wholly-owned subsidiary Stergic Retail Private Limited, the company entered pharmacy retail on 23 February 2026 with the first Stergic Pharmacy counter at Deep Vihar, Rohini Sector-22, Delhi. Consolidated FY26 revenue from operations stood at Rs 103.3759 crore, up 67.4% YoY, while standalone revenue grew 36.7% to Rs 3,778.57 lakhs. The subsidiary contributed Rs 416.76 lakhs to consolidated profit after tax of Rs 657.20 lakhs. Employee costs at 3.7% of revenue and other operating expenses at 4.6% are the disclosed cost lines. A new warehouse in Sonipat was taken on a five-year lease from 1 February 2026 to support distribution. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Branded pharmaceutical formulations, Pharmacy retail. Pharmaceutical formulations business with early-stage pharmacy retail expansion, BSE SME-listed
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 18 | 62 | 103 |
| EBITDA (ex other income) | — | — | — |
| margin % | — | — | — |
| Owners' profit | — | — | — |
| EPS, as reported (₹) | 3.24 | 12.91 | 13.46 |
| ROE % · ROCE % | — · 12.4 | — · 32.1 | — · 26.1 |
| Debt / equity (x) | — | — | — |
| Cash from operations | (4) | 1 | (13) |
| Capex | — | (2) | 0 |
| ₹ crore | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 22 | 40 | 43 | 60 |
| Profit before tax | 0 | 3 | 6 | 5 | 5 |
| Net profit | — | — | — | — | — |
| EPS (₹) | 0.00 | 4.85 | 8.07 | 7.63 | 5.83 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| FABTECH TECHNOLOGIES LTD | 650 | 10.6 | 1.55 | 10.6 | 9.1 | 10.7 | — | 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Royal Sense 3rd AGM on Sep 28; book closure Sep 21-27 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Royal Sense files FY26 Annual Report; standalone revenue up 37%, PAT flat | results | high | — | — |
| 5 Sept 2026 · AGM Notice: MD Reappointment, ESOP, Capital Hike and RPT Approvals | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Royal Sense board re-appoints MD, fixes 28 Sept AGM | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Clarification on share price movement to BSE | regulatory legal | medium | — | — |
| 1 Sept 2026 · BSE seeks clarification on significant price movement in Royal Sense | regulatory legal | medium | — | — |
| 17 Jul 2026 · Royal Sense board approves Rs 500Cr fundraise, doubles share capital | board shareholder meetings | medium | — | — |
| 16 Jul 2026 · Compliance Certificate for Q1 FY27 Dematerialization | compliance | minimal | — | — |
| 14 Jul 2026 · Board Meeting on July 17 to Consider Fund Raising and Capital Increase | board shareholder meetings | low | — | — |
| 13 Jul 2026 · Appointment of Ms. Somya Arora as Company Secretary | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| — |
| — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 3.6 | 20.0 | 1 of 17 | 100% |
| ROCE | 23.6 | 11.3 | 1 of 17 | 100% |
| Market cap | 51 | 175 | 12 of 17 | 31% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
